The 17% stock rally signals strong investor approval of COMPASS Pathways’ progress toward NDA submission and potential accelerated launch of COMP360 for treatment-resistant depression (TRD), supported by positive Phase III data and regulatory milestones.

• Confirmed rolling NDA submission underway with final data expected in early Q3, supporting potential approval later this year.
• Awarded the Commissioner's National Priority Voucher, enabling an ultra-accelerated FDA review timeline of 1-2 months post submission.
• Positive Phase III trial results affirm COMP360’s rapid onset and sustained efficacy for TRD, offering a differentiated profile from existing treatments.
• Commercial preparations progressing ahead of launch, including a growing salesforce and established psychedelic-specific CPT billing codes to facilitate reimbursement.
• Early-stage PTSD program advancing with site activations, expanding the potential addressable market beyond TRD.